COMPASS Pathways (CMPS) Q2 FY26 earnings call: guidance and Q&A

How do the new FDA guidelines, particularly the 12-month blinded durability requirement, affect COMP360's regulatory path and interpretation?

Management believes the guidelines will not impact COMP360's current regulatory approval process, as their Phase III design was aligned with the FDA prior to the draft guidelines. They acknowledge the 12-month blinded durability is a 'tall order' for future studies but note the guidelines' support for complementary Phase III designs.

“while the guidance is certainly interesting and we do have those on the 12 months blinded and that would seem like a pretty tall order in any psychiatry drug. We actually don't think it's going to impact the process of our regulatory approval at this stage.”

asked by Paul Matteis · answered by Kabir Nath

What are the anticipated reimbursement challenges for COMP360 at launch, and how will they affect the launch cadence?

The market access team is already engaging with payers and receiving positive feedback, especially for the TRD patient population. A field reimbursement team will be deployed at launch to help sites with coding and reimbursement. Decisions on rebating and formulary access negotiations will be made closer to launch.

“What we are doing now is our market [indiscernible] team is already engaging with payers, and they have been now for some time. We're getting very positive feedback from the payers, especially in this TRD patient population, where proving efficacy has almost been impossible to do in the past.”

asked by François Brisebois · answered by Lori Englebert

How are ongoing regulatory discussions progressing, and what are the expectations for DEA scheduling timelines?

Regulatory discussions are progressing well, with the rolling submission underway and FDA reviewing modules. The company is accelerating its 8-factor analysis for the FDA's Division of Controlled Substances and engaging with the DEA. While the DEA typically hits its 90-day timeline, the executive order in April could potentially pull rescheduling forward.

“We are accelerating our 8-factor analysis getting that to the CSS, FDA division of controlled substance as quickly as possible. And in hopes of that enabling a faster FDA and DEA coordination along the way.”

asked by Gavin Clark-Gartner · answered by Lori Englebert

What aspects of training will be offered to interventional psychiatry sites beyond coding, and how will this impact the 2027 rollout?

Training will cover two parts: general psychedelic training (already underway via third-party grants) and COMP360-specific monitoring/patient support training after final label approval. REMS certification training will also be provided. The time between approval and DEA rescheduling will be leveraged for site preparation. Field teams will educate prescribers and referring physicians, with significant support for education.

“We announced a little while ago that we are participating in grants for third-party companies to help with the training of the site. Both on psychedelics and as soon as COMPASS gets the final label on anything that's required for the monitoring time that the patient will be in the room.”

asked by Ritu Baral · answered by Lori Englebert

How does COMP360's value proposition compare to shorter-duration clinic products, and what are assumptions about other FDA-approved psilocybin molecules within the first year of COMP360's approval?

Duration in clinic is only one element; the psilocybin experience is inherently attractive. There's no strong economic argument for shorter duration if system capacity exists. Management believes they will be first to market, establishing a leadership position and proving clinical efficacy. They did not directly address the likelihood of other psilocybin approvals within the first year.

“duration in clinic is only one element of a product profile, yes. And I think from the perspective of the patient and the provider experience, it's not necessarily going to be the primary driver.”

asked by Sumant Kulkarni · answered by Kabir Nath

What will be the company's next major strategic priority after the successful launch of COMP360 for TRD?

PTSD is a clear strategic priority with an ongoing study. The company will prioritize other psychiatric conditions with interesting signals from IIS programs (e.g., OCD). Ex-U.S. partnering will be considered after U.S. approval. COMPASS aims to leverage its leadership position to play a role in broader psychedelic innovation and explore other assets.

“PTSD clearly is a strategic priority for us. So that study is underway, and we see that as a very important second indication.”

asked by Jay Olson · answered by Kabir Nath